Community Acquired Pneumonia - Pipeline Review, H1 2017

Publisher Name :
Date: 28-Feb-2017
No. of pages: 100
Inquire Before Buying

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Community Acquired Pneumonia - Pipeline Review, H1 2017, provides an overview of the Community Acquired Pneumonia (Infectious Disease) pipeline landscape.

Community-acquired pneumonia (CAP) is defined as pneumonia acquired outside a hospital or long-term care facility. Symptoms include cough, fever, shaking chills, confusion, headache and loss of appetite. Risk factors include chronic lung disease, cigarette smoking, dementia, stroke, brain injury, heart disease, liver cirrhosis and diabetes mellitus. Treatment includes antibiotics and healthy lifestyle.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Community Acquired Pneumonia - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Community Acquired Pneumonia (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Community Acquired Pneumonia (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Community Acquired Pneumonia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 5, 6, 2, 1 and 1 respectively.

Community Acquired Pneumonia (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note*: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Community Acquired Pneumonia (Infectious Disease).

  • The pipeline guide reviews pipeline therapeutics for Community Acquired Pneumonia (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

  • The pipeline guide reviews key companies involved in Community Acquired Pneumonia (Infectious Disease) therapeutics and enlists all their major and minor projects.

  • The pipeline guide evaluates Community Acquired Pneumonia (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

  • The pipeline guide reviews latest news related to pipeline therapeutics for Community Acquired Pneumonia (Infectious Disease)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

  • Find and recognize significant and varied types of therapeutics under development for Community Acquired Pneumonia (Infectious Disease).

  • Classify potential new clients or partners in the target demographic.

  • Develop tactical initiatives by understanding the focus areas of leading companies.

  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

  • Formulate corrective measures for pipeline projects by understanding Community Acquired Pneumonia (Infectious Disease) pipeline depth and focus of Indication therapeutics.

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Community Acquired Pneumonia - Pipeline Review, H1 2017

Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Community Acquired Pneumonia - Overview
Community Acquired Pneumonia - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Community Acquired Pneumonia - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Community Acquired Pneumonia - Companies Involved in Therapeutics Development
Aridis Pharmaceuticals LLC
BioAegis Therapeutics Inc
Biotest AG
InflaRx GmbH
ioGenetics Inc
Kyorin Pharmaceutical Co Ltd
Lascco SA
Melinta Therapeutics Inc
Merck & Co Inc
Nabriva Therapeutics AG
Paratek Pharmaceuticals Inc
TaiGen Biotechnology Co Ltd
Takeda Pharmaceutical Company Ltd
Tetraphase Pharmaceuticals Inc
TiGenix NV
Wockhardt Ltd
Community Acquired Pneumonia - Drug Profiles
BT-086 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CAL-02 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ceftaroline fosamil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cx-611 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DBAF-301 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
delafloxacin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IFX-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lascufloxacin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lefamulin acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Nafithromycin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nemonoxacin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
omadacycline tosylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PneumoMab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Plasma Gelsolin Replacement for Community Acquired Pneumonia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
solithromycin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tosatoxumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TP-271 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Community Acquired Pneumonia - Dormant Projects
Community Acquired Pneumonia - Discontinued Products
Community Acquired Pneumonia - Product Development Milestones
Featured News & Press Releases
Feb 02, 2017: Nabriva Therapeutics Confirms No Sample Size Adjustment Required for LEAP 1 Phase 3 Trial of Lefamulin in Community Acquired Bacterial Pneumonia
Jan 18, 2017: Paratek Announces Completion of Enrollment in Omadacycline Phase 3 Community-Acquired Bacterial Pneumonia Study
Dec 29, 2016: Cempra Receives Complete Response Letter From FDA For Solithromycin NDAs
Dec 20, 2016: Nabriva Achieves 60% Randomization Target in LEAP 1 Phase 3 Trial in Community Acquired Bacterial Pneumonia
Dec 13, 2016: Paratek Advances Timing of Top-Line Data for Phase 3 Community Acquired Bacterial Pneumonia Study to the Second Quarter of 2017
Dec 05, 2016: Launch of Phase III clinical trial for the new macrolide antibiotic "T-4288" in Japan
Nov 04, 2016: FDA Advisory Committee Votes That Efficacy Results of Cempras Solithromycin Outweigh Risks for Community-Acquired Bacterial Pneumonia
Nov 01, 2016: Cempra Receives $10 Million Milestone Payment From Toyama Chemical (a Subsidiary of FUJIFILM Holdings Corporation) as Solithromycin Progresses to Phase 3 Studies in Japan
Oct 31, 2016: Nabriva Presents Research on Lefamulin at IDWeek 2016
Oct 20, 2016: Nabriva Announces Presentations at Upcoming IDWeek 2016
Aug 30, 2016: Cempra to Present Solithromycin at FDA Antimicrobial Drugs Advisory Committee Meeting on November 4, 2016
Aug 25, 2016: Cempras Pivotal Phase 3 SOLITAIRE-IV Study of IV to Oral Solithromycin Published in Clinical Infectious Diseases
Aug 23, 2016: Cempra Announces European Medicines Agency Validates MAA for Solithromycin for Treatment of CABP
Aug 11, 2016: Cempra Appoints Dr. David Zaccardelli to Board of Directors
Jul 05, 2016: Cempra Announces FDA Acceptance of Solithera New Drug Applications in the Treatment of Community-Acquired Bacterial Pneumonia
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables

Number of Products under Development for Community Acquired Pneumonia, H1 2017
Number of Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Community Acquired Pneumonia - Pipeline by Aridis Pharmaceuticals LLC, H1 2017
Community Acquired Pneumonia - Pipeline by BioAegis Therapeutics Inc, H1 2017
Community Acquired Pneumonia - Pipeline by Biotest AG, H1 2017
Community Acquired Pneumonia - Pipeline by InflaRx GmbH, H1 2017
Community Acquired Pneumonia - Pipeline by ioGenetics Inc, H1 2017
Community Acquired Pneumonia - Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2017
Community Acquired Pneumonia - Pipeline by Lascco SA, H1 2017
Community Acquired Pneumonia - Pipeline by Melinta Therapeutics Inc, H1 2017
Community Acquired Pneumonia - Pipeline by Merck & Co Inc, H1 2017
Community Acquired Pneumonia - Pipeline by Nabriva Therapeutics AG, H1 2017
Community Acquired Pneumonia - Pipeline by Paratek Pharmaceuticals Inc, H1 2017
Community Acquired Pneumonia - Pipeline by TaiGen Biotechnology Co Ltd, H1 2017
Community Acquired Pneumonia - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017
Community Acquired Pneumonia - Pipeline by Tetraphase Pharmaceuticals Inc, H1 2017
Community Acquired Pneumonia - Pipeline by TiGenix NV, H1 2017
Community Acquired Pneumonia - Pipeline by Wockhardt Ltd, H1 2017
Community Acquired Pneumonia - Dormant Projects, H1 2017
Community Acquired Pneumonia - Discontinued Products, H1 2017

List of Figures

Number of Products under Development for Community Acquired Pneumonia, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products by Targets, H1 2017
Number of Products by Stage and Targets, H1 2017
Number of Products by Mechanism of Actions, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017
  • Renewable Energy Sources Needs To Boost Global Microgrids Market
    The global market for microgrid was worth US$13.3 billion in 2015, and is anticipated to touch an estimate of US$35.2 billion by 2020. Dealers in the market for microgrids are incessantly improving the network hosting capability for renewable energy resources to excerpt an extreme amount from it, in addition to commercialization of classically costly renewable […]
  • Manufacturing Trends In The Coming Days
    The manufacturing industry may be encountering some breezes, but it is irrefutably in the middle of a technological revival that is altering the appearance, structures, and practices of the modern factory. Notwithstanding the jeopardies and in spite of recent history industrial manufacturing enterprises cannot afford to disregard these developments. Few of the trends to look […]
  • Top 10 Emerging Technologies
    The World Economic Forum (WEF) and Scientific American lately unveiled the major technological innovation list of the top ten emerging technologies. This list emphasizes on the technological developments which have the supremacy to transform industries, protect the planet, and improve lives. It also presents an opening to discuss any societal, human, economic or environmental jeopardies […]
  • Global Biosimilars Market To Be Led By Novartis by 2020
    Biologics, which are typically inoculated or injected, are formed in living entities, making them more challenging and costly to manufacture than the usual pills contrived from chemicals. Observing that mock-ups are mostly identical to the prototypes has also modelled specific scientific and regulatory tasks. But the US FDA and European supervisors lately have acknowledged new […]
  • Global Thyroid Gland Disorder Treatment Market To Grow Steadily
    The global thyroid gland disorder treatment market was worth US$1.8 billion in 2014 and is projected to reach a market value of US$2.4 billion in 2023 intensifying at a CAGR of 3.1% from 2015 to 2023.  The thyroid gland produces thyroid hormones that control some of the most essential functions in the human body such as stimulating […]
  • United States Ampicillin Market Report 2017
    Published: 19-Jun-2017        Price: US 3800 Onwards        Pages: 100
    In this report, the United States Ampicillin market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report splits the United States market into seven regions: - The West - Southwest - The Middle Atlantic - New England - The South - The Midwest with sales (volume), revenue (value), market share and growth rate of Ampic......
  • EMEA (Europe, Middle East and Africa) Ganciclovir Market Report 2017
    Published: 15-Jun-2017        Price: US 4000 Onwards        Pages: 103
    In this report, the EMEA Ganciclovir market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K Pcs), revenue (Million USD), market share and growth rate of Ganciclovir for these regions, from 2012 to 2022 (forecast) - Europe: Germany, France, UK, Russia, Italy and Benelux; - Middle E......
  • Global Herpes Treatment Market 2017-2021
    Published: 14-Jun-2017        Price: US 3500 Onwards        Pages: 82
    Herpesviruses belong to double-stranded DNA viruses, which are responsible for a large number of diseases in humans and animals. There are eight types of human herpesvirus (HHV) that affects humans. Among these, herpes simplex virus (HSV) and varicella-zoster virus (VZV) are the two most commonly found HHVs that causes severe infections in humans. HSV is further segmented into oral herpes and genital herpes. The analysts forecast global herpes treatment market to grow at a CAGR of 12.......
  • Global Clotrimazole Market Professional Survey Report 2017
    Published: 14-Jun-2017        Price: US 3500 Onwards        Pages: 113
    This report studies Clotrimazole in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022. This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering - Bayer - Erregierre - F.I.S. - Amoli Organics - CordenPharma......
  • Global Ampicillin Sales Market Report 2017
    Published: 13-Jun-2017        Price: US 4000 Onwards        Pages: 105
    In this report, the global Ampicillin market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (K MT), revenue (Million USD), market share and growth rate of Ampicillin for these regions, from 2012 to 2022 (forecast), covering - United States - China - Europe - Japan - Southeas......
  • Burkholderia pseudomallei Infections (Melioidosis) - Pipeline Review, H1 2017
    Published: 23-May-2017        Price: US 2000 Onwards        Pages: 52
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Burkholderia pseudomallei Infections (Melioidosis) - Pipeline Review, H1 2017, provides an overview of the Burkholderia pseudomallei Infections (Melioidosis) (Infectious Disease) pipeline landscape.Burkholderia pseudomallei are a gram negative, bipolar, aerobic, motile rod-shaped soil dwelling bacterium. The bacterium can infect both animals and humans through direct contact via inhalation, ingestion, or open ......
  • Escherichia coli Infections - Pipeline Review, H1 2017
    Published: 23-May-2017        Price: US 2000 Onwards        Pages: 152
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Escherichia coli Infections - Pipeline Review, H1 2017, provides an overview of the Escherichia coli Infections (Infectious Disease) pipeline landscape.Escherichia coli (E. coli) bacteria normally live in the intestines of healthy people and animals. Escherichia coli infections are caused by coming into contact with the feces, or stool, of humans or animals or drink water or eat food that has been contaminated......
  • Tularaemia - Pipeline Review, H1 2017
    Published: 23-May-2017        Price: US 2000 Onwards        Pages: 68
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Tularaemia - Pipeline Review, H1 2017, provides an overview of the Tularaemia (Infectious Disease) pipeline landscape.Tularaemia is an infection caused due to a bacterium called Francisella tularensis. Humans become infected mainly through the bite of arthropods, particularly ticks and mosquitoes, and through the skin, conjunctival sac or oropharyngeal mucosa, by direct contact with infected animals or animal ......
  • Diphtheria - Pipeline Review, H1 2017
    Published: 23-May-2017        Price: US 2000 Onwards        Pages: 68
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diphtheria - Pipeline Review, H1 2017, provides an overview of the Diphtheria (Infectious Disease) pipeline landscape.Diphtheria is a bacterial infection that affects the membranes of the throat and nose. If left untreated, diphtheria can cause severe damage to kidneys, nervous system, and heart. Symptoms include sore throat and hoarseness, swollen glands (enlarged lymph nodes) in neck, nasal discharge, fever ......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs